New PCV Product Assessment for Vaccine Decision-Makers

The availability of multiple pneumococcal vaccines, with overlapping but non-identical characteristics, including formulation, poses decision-making challenges for countries and partners. The PCV Product Assessment addresses the pressing need for a vaccine decision-making framework—populated by unbiased evidence—that helps to inform product choice, in order to optimize and sustain PCV use.

Download the PCV Product Assessment (April 2017, 162 pages)

What is the scope of this document?

This technical document synthesizes the epidemiologic and biologic evidence regarding pneumococcal conjugate vaccine (PCV) products, as well as the programmatic considerations surrounding performance, effectiveness, and impact for current PCVs: 10-valent (PCV10) and 13-valent products (PCV13).
The information here focuses on pre-qualified and globally marketed PCVs, but does not include a systematic review of evidence from previously marketed products (i.e. PCV7), or information on unlicensed products of the past (i.e. PCV9, PCV11), or those that are currently under evaluation.
This document should not be viewed as formal WHO recommendations as it has not yet undergone formal WHO guideline review.
The document is not intended as the primary source of information to support decision-making about whether to include PCV in the vaccine program or on dosing schedules, and it does not itself provide any recommendations for product choice.

How can countries use this document?

As a technical tool to inform PCV decision-making on product choice at the time of introduction and within established PCV programs
As a resource to readily access key evidence, data and tools for PCV product choice

How can Gavi use this document?

As a technical tool to inform PCV demand forecasts, including supply planning for country allocation
As a resource to readily access key evidence, data and tools for PCV product choice
As a resource to create country guidance on PCV product choices